Format

Send to

Choose Destination
Oncotarget. 2016 Mar 1;7(9):9645-51. doi: 10.18632/oncotarget.7506.

A follow-up analysis of positron emission tomography/computed tomography in detecting hidden malignancies at the time of diagnosis of membranous nephropathy.

Author information

1
Department of Nephrology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
2
Department of Nuclear Medicine and PET Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
3
Medical Genetics Center of Guangdong Women and Children Hospital, Guangzhou, China.

Abstract

Membranous nephropathy (MN) is the most common kidney disease reported in a variety of malignant diseases. Search for an occult malignancy in MN has presented special challenges. 124 MN patients with a physical examination not suspicious for cancer underwent screening for an occult malignancy with either 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scanning (n = 49) or conventional screening (n = 75) at the time of diagnosis of MN, and were followed up (median,28 months). 154 patients who refused to undergo any screening were followed up (median, 30 months). In FDG-PET/CT cohort, 5 (10.20%) patients were screened and confirmed as malignancy, in contrast, 1 (1.33%) patient in conventional screening cohort. During follow-up, none of malignancy was detected in FDG-PET/CT cohort, 3(4.05%) patients in conventional screening cohort, and 8(5.19%) patients in no-screening cohort. All 6 cases of cancer were detected at early stages and underwent curative resection, and after the resection, proteinuria decreased. In contrast, 11 cases of cancer detected during follow-up died without any remission of proteinuria. These preliminary data provide the first evidence for a potential cancer surveillance that the malignancy screening either through conventional or by PET-CT at the diagnosis of MN led to an early diagnosis and curative treatment.

KEYWORDS:

PET/CT; Pathology Section; malignancy; membranous nephropathy

PMID:
27009881
PMCID:
PMC4891073
DOI:
10.18632/oncotarget.7506
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center